Lyon

France

875 total trials 407 recruiting

Filter these 875 trials by phase, condition, sponsor and more.

Open in Search →

A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers Ended

2023-507674-41-00 1 Advanced high-grade serous ovarian cancer (OC)
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati … Ended

2023-509227-41-00 4 Low risk of disease recurrence, defined by the following criteria: - A
Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended

2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI) Ended

2024-511857-23-00 4 cancerology
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative settin … Ended

2024-514078-29-00 4 gastric and gastro-oesophageal junction adenocarcinomas
A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons … Ended

2024-515393-27-00 4 Nonsquamous non-small cell lung cancer
Trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer Ended

2024-516558-24-00 4 Pancreatic (PAAD)
Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre … Ended

2024-516724-33-00 9 Advanced/metastatic gynecological cancer overexpressing FGFR2b
DCC-3084 monotherapy in patients with solid tumors Ended

2024-517829-12-00 7 Solid tumors driven by the MAPK Pathway
First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors Ended

2024-517984-21-00 1 Advanced Solid Tumors
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) … Ended

2024-519258-35-00 4 stomach cancer

Showing 865–875 of 875 trials